Compounded Drugs Shake Up Obesity Treatment Market
Novo Nordisk CEO Mike Doustdar highlighted the growing use of compounded GLP-1 drugs in the U.S., which are cheaper but unapproved alternatives for obesity treatment. Despite health risks, cost-sensitive patients opt for these versions. Novo is responding with new pricing and access strategies to regain market share.